| Revision as of 20:30, 10 April 2024 edit66.244.207.138 (talk)No edit summary← Previous edit | Latest revision as of 05:34, 18 August 2024 edit undoCharles Matthews (talk | contribs)Autopatrolled, Administrators360,572 edits wording | ||
| Line 43: | Line 43: | ||
| | molecular_weight = | | molecular_weight = | ||
| }} | }} | ||
| '''Idursulfase''' (brand name '''Elaprase'''), manufactured by ], is a drug used to treat ] (also called ]).<ref name="pmid17459751">{{cite journal |vauthors=Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC |title=Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II |journal=Mol. Genet. Metab. |volume=91 |issue=2 |pages=183–90 |year=2007 |pmid=17459751 |doi=10.1016/j.ymgme.2007.03.003}}</ref> It is a purified form of |
'''Idursulfase''' (brand name '''Elaprase'''), manufactured by ], is a drug used to treat ] (also called ]).<ref name="pmid17459751">{{cite journal |vauthors=Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC |title=Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II |journal=Mol. Genet. Metab. |volume=91 |issue=2 |pages=183–90 |year=2007 |pmid=17459751 |doi=10.1016/j.ymgme.2007.03.003}}</ref> It is a purified form of ], a ] enzyme, and is produced by ] in a human cell line. | ||
| It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.<ref>{{cite news |url=http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |title=Drug approved to treat rare but potentially deadly disease |access-date=2011-04-29 |archive-url=https://web.archive.org/web/20110224123252/http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |archive-date=2011-02-24 |url-status=dead }}</ref><ref>, Matthew Herper, Forbes, Feb. 22, 2010</ref><ref>, Barbara Kollmeyer, Marketwatch, Fed. 3, 2016</ref> | It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.<ref>{{cite news |url=http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |title=Drug approved to treat rare but potentially deadly disease |access-date=2011-04-29 |archive-url=https://web.archive.org/web/20110224123252/http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |archive-date=2011-02-24 |url-status=dead }}</ref><ref>, Matthew Herper, Forbes, Feb. 22, 2010</ref><ref>, Barbara Kollmeyer, Marketwatch, Fed. 3, 2016</ref> | ||
Latest revision as of 05:34, 18 August 2024
Pharmaceutical compound| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| License data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| (what is this?) (verify) | |
Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II). It is a purified form of iduronate-2-sulfatase, a lysosomal enzyme, and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.
References
- "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
- "Drug approved to treat rare but potentially deadly disease". Archived from the original on 2011-02-24. Retrieved 2011-04-29.
- Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
- , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016
External links
- idursulfase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
 | This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |